Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

Gastroenterology

Volumn 140, Issue 2, 2011, Pages 497-507.e2

  Salem, Riad ^a   Lewandowski, Robert J ^a   Kulik, Laura ^a   Wang, Edward ^a   Riaz, Ahsun ^a   Ryu, Robert K ^a   Sato, Kent T ^a   Gupta, Ramona ^a   Nikolaidis, Paul ^a   Miller, Frank H ^a   Yaghmai, Vahid ^a   Ibrahim, Saad M ^a   Senthilnathan, Seanthan ^a   Baker, Talia ^a   Gates, Vanessa L ^a   Atassi, Bassel ^a   Newman, Steven ^a   Memon, Khairuddin ^a   Chen, Richard ^a   Vogelzang, Robert L ^a   Nemcek, Albert A ^a   Resnick, Scott A ^a   Chrisman, Howard B ^a   Carr, James ^a   Omary, Reed A ^a   Abecassis, Michael ^a   Benson III, Al B ^a   Mulcahy, Mary F ^a   more..

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Clinical Trial; Comparative Effectiveness; Liver Cancer; Radiotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; DOXORUBICIN; IODINATED POPPYSEED OIL; MICROSPHERE; MITOMYCIN; YTTRIUM 90;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ARTIFICIAL EMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CHILL; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE COURSE; ENZYME ACTIVITY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOEMBOLIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VOMITING;

EID: 79251575901     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.10.049     Document Type: Article

References (44)

1. H.B. El-Serag Hepatocellular carcinoma and hepatitis C in the United States Hepatology 36 2002 S74 S83
2. V. Mazzaferro, E. Regalia, and R. Doci Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699
3. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
4. A.L. Cheng, Y.K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
5. M.B. Thomas, D. Jaffe, and M.M. Choti Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting J Clin Oncol 28 2010 3994 4005
6. A.B. Benson III, T.A. Abrams, and E. Ben-Josef NCCN clinical practice guidelines in oncology: hepatobiliary cancers J Natl Compr Canc Netw 7 2009 350 391
7. R. Salem, R.J. Lewandowski, and M.F. Mulcahy Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
8. P.V. Pandharipande, and G.S. Gazelle Comparative effectiveness research: what it means for radiology Radiology 253 2009 600 605
9. S.R. Tunis, J. Benner, and M. McClellan Comparative effectiveness research: policy context, methods development and research infrastructure Stat Med 29 2010 1963 1976
10. H.B. El-Serag, J. Talwalkar, and W.R. Kim Efficacy, effectiveness, and comparative effectiveness in liver disease Hepatology 52 2010 403 407
11. P.H. Conway, and C. Clancy Charting a path from comparative effectiveness funding to improved patient-centered health care JAMA 303 2010 985 986
12. R.J. Lewandowski, M.F. Mulcahy, and L.M. Kulik Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort Radiology 255 2010 955 965
13. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
14. J. Bruix, M. Sherman, J.M. Llovet European Association for the Study of the Liver Clinical management of hepatocellular carcinoma Conclusions of the Barcelona-2000 EASL conference J Hepatol 35 2001 421 430
15. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
16. J. Bruix, M. Sala, and J.M. Llovet Chemoembolization for hepatocellular carcinoma Gastroenterology 127 2004 S179 S188
17. R. Salem, and K.G. Thurston Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations J Vasc Interv Radiol 17 2006 1251 1278
18. A. Riaz, R.K. Ryu, and L.M. Kulik Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival J Clin Oncol 27 2009 5734 5742
19. A. Forner, C. Ayuso, and M. Varela Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
20. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. A. Riaz, F.H. Miller, and L.M. Kulik Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma JAMA 303 2010 1062 1069
22. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
23. D.R. Cox, and D. Oaks Analysis of survival data 1984 Chapman & Hall London, England
24. R. Lencioni, D. Cioni, and L. Crocetti Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation Radiology 234 2005 961 967
25. J.M. Llovet, M.I. Real, and X. Montana Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
26. K. Leelawat, P. Laisupasin, and A. Kiatdilokrut The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE) J Med Assoc Thai 91 2008 1539 1543
27. S. Virmani, T.K. Rhee, and R.K. Ryu Comparison of hypoxia-inducible factor-1α expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors J Vasc Interv Radiol 19 2008 1483 1489
28. K. Sato, R.J. Lewandowski, and J.T. Bui Treatment of unresectable primary and metastatic liver cancer with Yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization Cardiovasc Intervent Radiol 29 2006 522 529
29. L.M. Kulik, B.I. Carr, and M.F. Mulcahy Safety and efficacy of (90)Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis Hepatology 47 2007 71 81
30. J.F. Geschwind, R. Salem, and B.I. Carr Yttrium-90 microspheres for the treatment of hepatocellular carcinoma Gastroenterology 127 2004 S194 S205
31. R.J. Lewandowski, L.M. Kulik, and A. Riaz A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization Am J Transplant 9 2009 1920 1928
32. A.M. Garber, and S.R. Tunis Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 360 2009 1925 1927
33. J.E. Goin, J.E. Dancey, and C.A. Roberts Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemo-embolization versus Yttrium-90 glass microspheres World J Nucl Med 3 2004 49 56
34. J. Lammer, K. Malagari, and T. Vogl Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
35. S.L. Chan, F.K. Mo, and P.J. Johnson New utility of an old marker: serial α-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy J Clin Oncol 27 2009 446 452
36. A. Riaz, L. Kulik, and R.J. Lewandowski Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres Hepatology 49 2009 1185 1193
37. A. Riaz, R.J. Lewandowski, and L. Kulik Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization Cardiovasc Intervent Radiol 33 2010 1143 1152
38. B. Gyorffy, A. Gyorffy, and Z. Tulassay The problem of multiple testing and solutions for genome-wide studies Orv Hetil 146 2005 559 563
39. T.J. Cleophas, and A.H. Zwinderman Clinical trials are often false positive: a review of simple methods to control this problem Curr Clin Pharmacol 1 2006 1 4
40. D.B. Rubin On the limitations of comparative effectiveness research Stat Med 29 2010 1991 1997
41. S.L. Normand, and B.J. McNeil What is evidence? Stat Med 29 2010 1985 1988 discussion 19961997
42. D.A. Kooby, V. Egnatashvili, and S. Srinivasan Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma J Vasc Interv Radiol 21 2010 224 230
43. D. D'Avola, M. Lnarrairaegui, and J.I. Bilbao A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma Hepatogastroenterology 56 2009 1683 1688
44. B.I. Carr, V. Kondragunta, and S.C. Buch Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a Two-Cohort Study Cancer 116 2010 1305 1314